Corix Bioscience (Corix Bioscience) EBIT : $-4.94 Mil (TTM As of Sep. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Corix Bioscience EBIT?

Corix Bioscience's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2017 was $-0.28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2017 was $-4.94 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Corix Bioscience's annualized ROC % for the quarter that ended in Sep. 2017 was -16.81%. Corix Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 was -75.03%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Corix Bioscience EBIT Historical Data

The historical data trend for Corix Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corix Bioscience EBIT Chart

Corix Bioscience Annual Data

Trend

Jan09

Jan10

Jan11

Jan12

Jan13

Jan14

Jan15

Dec16

EBIT

Get a 7-Day Free Trial

-0.08

-1.70

-1.72

-0.05

-4.05

Corix Bioscience Quarterly Data
	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
EBIT	Get a 7-Day Free Trial															-0.33	-3.14	-0.07	-1.46	-0.28

Competitive Comparison of Corix Bioscience's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corix Bioscience's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's EV-to-EBIT falls into.

Corix Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.94 Mil.

Corix Bioscience (GREY:CXBS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Corix Bioscience's annualized ROC % for the quarter that ended in Sep. 2017 is calculated as:

	ROC % (Q: Sep. 2017 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2017 )	+	Invested Capital (Q: Sep. 2017 ))	/ count )
=	-1.2 * ( 1 - 0% )	/	( (10.333	+	3.947)	/ 2 )
=	-1.2	/	7.14
=	-16.81 %

where

	Invested Capital		(Q: Jun. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10.457	-	0.827	-	( 0.144	-	max(0, 1.205	-	0.502	+	0.144	))
=	10.333

	Invested Capital		(Q: Sep. 2017 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.344	-	0.036	-	( 0.361	-	max(0, 0.786	-	4.011	+	0.361	))
=	3.947

Note: The Operating Income data used here is four times the quarterly (Sep. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Corix Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2017 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2017		Q: Sep. 2017
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.124	/	( ( (0 + max(-0.906, 0))	+	(0.082 + max(2.914, 0)) )	/	2 )
=	-1.124	/	( ( 0	+	2.996 )	/	2 )
=	-1.124	/	1.498
=	-75.03 %

where Working Capital is:

	Working Capital		(Q: Jun. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.28)	-	(0.827	+	0	+	0.359)
=	-0.906

	Working Capital		(Q: Sep. 2017 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.045	+	3.605)	-	(0.036	+	0	+	0.7)
=	2.914

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Corix Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2017 )
	=	-4.941	/	0.000
	=	%

Corix Bioscience EBIT Related Terms

Thank you for viewing the detailed overview of Corix Bioscience's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Corix Bioscience (Corix Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Corix Bioscience Inc (GREY:CXBS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085

Website

http://www.corixbioscience.com

Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

Corix Bioscience (Corix Bioscience) Headlines

No Headlines